A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade. When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain. Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity. This article discusses the mechanism of action of bupropion and relates the drug's neuropharmacologic effects to its clinical efficacy and tolerability profiles. DATA SOURCES: Data were obtained via the MEDLINE database in an English-language search spanning the period 1965 to May 2002 and using the search terms bupropion, bupropion SR, and antidepressants, as well as from the manufacturer's bupropion databases. CONCLUSIONS: The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors. Dual norepinephrine and dopamine reuptake inhibition is associated with a unique clinical profile. Bupropion has demonstrated efficacy comparable to that of other antidepressants. However, because bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, common antidepressant-associated side effects, such as sexual dysfunction, weight gain, and sedation, are not associated with bupropion therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bupropion is a second-generation AD that acts as a selective inhibitor of catecholamines' (noradrenaline and dopamine) reuptake, devoid of any serotonergic; antihistamine; or anticholinergic properties (Stahl et al., 2004).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Stahl et al., 2004
In the citing paper
“Inhibition of catecholamine reuptake is one of bupropion’s mechanisms of action [215].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, J. R., Freemantle, N., Mason, J. M., Eccles, M., & Boynton, J. R. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 125
RetractedGoodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“cause depression and modulate responses to antidepressants.(14,16,19) Several observations support an “upstream””
BackgroundUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180 · cited 1×
“Antidepressants may thus play a neuroprotective role, a possibility supported by observations that hippocampal neurogenesis may be required for the behavior effects of antidepressants in mice(23) and that progressive loss of hippocampal volume occurs during chronically untreated depression in humans.(24,25)”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“For example, antidepressants differ by more than 1000fold in potency at inhibiting monoamine reuptake, yet their efficacies are comparable and seemingly unrelated to potency.(21) Third, although all antidepressants enhance monoaminergic neurotransmission, they do so via disparate mechanisms, consistent with the possib…”
Background(2000) · PubMed · Cited by 685
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citation
Research works printed but not linked: 27
- Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph. 1993;11(1):2–14. [PubMed] [Google Scholar]
- GlaxoSmithKline. data on file, Research Triangle Park, NC. 2002. [Google Scholar]
- Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000 [Google Scholar]
- Remeron [package, insert]. West Orange, NJ: Organon. 2002. [Google Scholar]
- Serzone [package, insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2002. [Google Scholar]
- Holden C. ed. Random samples: don't go off the Prozac. Science. 2003 301:760–761. [Google Scholar]
- Szabó Z, Àrgyelán M, and Kanyó B. et al. The effect of bupropion on the activity of dopamine transporter in depression: preliminary results [abstract]. Eur Neuropsychopharmacol. 2003 13(suppl 4):S210. [Google Scholar]
- American Psychiatric Association. Major Depressive Disorder: A Patient and Family Guide, 2001. Available at: www.psych.org. Accessed June 7, 2001. [Google Scholar]
- Geddes JR, Freemantle N, and Mason J. et al. SSRIs versus other anti-depressants for depressive disorder. Cochrane Database Syst Rev 2000(2):CD001851. [DOI] [PubMed] [Google Scholar]
- Thase ME, Haight BR, and Richard NE. et al. Remission rates following therapy with bupropion or SSRIs. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion [poster]. Presented at the 146th annual meeting of the American Psychiatric Association. 22–27May1993 San Francisco, Calif. [Google Scholar]
- Ramasubbu R. Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs. Ann Pharmacother. 2002;36:634–640. doi: 10.1345/aph.10408. [DOI] [PubMed] [Google Scholar] · doi:10.1345/aph.10408 · Paper page
- Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7:73–75. [PubMed] [Google Scholar]
- Yeghiya M, Danielyan A, and Khachatur G. et al. Augmentation of SSRIs with bupropion in treatment resistant depression in adolescents [abstract]. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- DeBattista C, Solvason HB, and Fleming S. et al. A placebo-controlled, double-blind study of bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 154th annual meeting of the American Psychiatric Association. 5–10May2001 New Orleans, La. [DOI] [PubMed] [Google Scholar]
- Solvason HB, DeBattista C, and Kendrick E. et al. Bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). May 30–June 2, 2000 Boca Raton, Fla. [Google Scholar]
- Johnston JA, Schmidt G, and Ascher J. et al. Pharmacokinetic optimization of bupropion SR for smoking cessation. Drugs. 2002 62(suppl 2):11–24. [DOI] [PubMed] [Google Scholar]
- Hudziak JJ, Wilens TE, and Rosenthal NE. et al. The efficacy of extended-release bupropion in adult ADHD [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Rosenthal NE, Modell JG, and Harriett A. et al. Wellbutrin XL for the prevention of seasonal depressive episodes [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Clayton AH, West SG. The effects of antidepressants on human sexuality. Primary Psychiatry. 2003;10:62–70. [Google Scholar]
- Westlund R, Haight BR, and Harriett A. et al. Effect on body weight of bupropion in patients with major depression [poster]. Presented at the 16th Annual US Psychiatric & Mental Health Congress. 6–9November2003 Orlando, Fla. [Google Scholar]
- Celexa [package, insert]. St Louis, Mo: Forest Laboratories. 2002. [Google Scholar]
- Prozac [package, insert]. Indianapolis, Ind: Eli Lilly and Company. 2002. [Google Scholar]
- Paxil [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
- Zoloft [package, insert]. New York, NY: Pfizer Inc. 2002. [Google Scholar]
- Effexor [package, insert]. Philadelphia, Pa: Wyeth. 2002. [Google Scholar]
- Wellbutrin [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
Cited by
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“It is well established that bupropion has little direct effect on 5HT function (Stahl et al., 2004).”
BackgroundMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“However, if the patient was nonresponsive to the initial SSRI, switching out of class to a SNRI (i.e., venlafaxine), NDRI or TCA, is recommended (Ruhé et al., 2006b; Rush et al., 2006).”
BackgroundA brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
“Bupropion IR requires three daily doses; thus, to reduce daily dosing regimens, the sustained-release (SR) and extended-release (XL) were developed and approved by the FDA in 1996 and 2003, respectively (Fava et al., 2005; Stahl et al., 2004).”
BackgroundInfluentialWadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
A clinical perspective of obesity, metabolic syndrome and cardiovascular disease
Han, T. S., & Lean, M. E. (2016) · JRSM Cardiovascular Disease · doi:10.1177/2048004016633371 · Cited by 500
Metadata
- Authors
- Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S.
- Affiliations
- University of California San Diego (US)
- St. John Hospital & Medical Center (US)
- Corresponding author
- Modell, Jack G.
- ORCID
- Stahl, Stephen M.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-08-13
- Volume
- 6
- Issue
- 4
- Pages
- 159-166
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- PMC
- PMC514842
- OpenAlex
- W2046809238
- Cited by
- 495
- References
- 92
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 31 · 2023: 33 · 2022: 35 · 2021: 27 · 2020: 27 · 2019: 19 · 2018: 36 · 2017: 25 · 2016: 29 · 2015: 23 · 2014: 19 · 2013: 20 · 2012: 15
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- bupropion, norepinephrine reuptake inhibition, dopamine uptake inhibition, antidepressant mechanism, antidepressant efficacy, antidepressant tolerability, sexual dysfunction, weight gain, sedation, serotonergic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.